Literature DB >> 8018536

A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.

S Iinuma1, S S Farshi, B Ortel, T Hasan.   

Abstract

5-Aminolaevulinic acid (ALA)-induced porphyrin biosynthesis and phototoxicity in vitro was investigated in five malignant and two normal cell lines. Intracellular protoporphyrin IX (PpIX) content was quantified by extraction and fluorescence spectroscopy. Cellular PpIX content did not always correlate with cell proliferation rate as measured by the doubling times of cell lines. Cellular efflux of PpIX was also investigated. In a bladder carcinoma cell line, the observed rapid efflux was not blocked by verapamil, an inhibitor of the P-glycoprotein efflux pump. These data support the view that cellular PpIX accumulation is a dynamic process that is determined by both the efflux of PpIX from the cells and enzyme activities in the haem biosynthesis pathway. Desferrioxamine (desferal), a modulator of PpIX biosynthesis, enhanced ALA-induced cellular PpIX content significantly in all carcinoma cell lines but not in non-malignant cell lines. The enhanced PpIX cellular accumulation is attributed to inhibition of ferrochelatase activity, the enzyme responsible for the conversion of PpIX to haem. PpIX-mediated cellular photodestruction following irradiation with an argon ion laser at 514.5 nm was determined by the 'MTT assay'. There appeared to be a 'threshold' effect of cellular PpIX content; cells that synthesised less than 140 ng/mg-1 protein exhibited very little phototoxic damage, while cell lines having greater than 140 ng PpIX/mg-1 protein [corrected] exhibited a consistent phototoxic response. Among the cell lines which did undergo phototoxic damage, there was not a strict correlation between PpIX cellular content and ALA-induced phototoxicity. Desferal enhanced the PpIX content and phototoxic effect in the responsive cells. Fluorescence microscopy of the ALA-treated cells revealed marked accumulation of PpIX in mitochondria (rhodamine 123 co-staining). That the primary site of phototoxic damage is also the mitochondria was confirmed by electron micrographs of cells photosensitised with ALA-induced PpIX, which showed swelling of mitochondria within minutes after irradiation while other suborganelles appeared to be unaffected. The repair or further destruction of the mitochondria was fluence and cell-type dependent. The data from this study suggest that the basis of increased ALA-induced PpIX accumulation in tumours is a combination of various aspects of the metabolic process and pharmacokinetics and that the efficacy of photodestruction of malignancy will be determined not only by the rate of PpIX synthesis but also by specific cellular and tissue characteristics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018536      PMCID: PMC2033301          DOI: 10.1038/bjc.1994.244

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Effects by heme, insulin, and serum albumin on heme and protein synthesis in chick embryo liver cells cultured in a chemically defined medium, and a spectrofluorometric assay for porphyrin composition.

Authors:  S Granick; P Sinclair; S Sassa; G Grieninger
Journal:  J Biol Chem       Date:  1975-12-25       Impact factor: 5.157

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  Kinetics of porphyrin accumulation in cultured epithelial cells exposed to ALA.

Authors:  H Fukuda; A M Batlle; P A Riley
Journal:  Int J Biochem       Date:  1993-10

5.  Endogenous porphyrin distribution induced by 5-aminolaevulinic acid in the tissue layers of the gastrointestinal tract.

Authors:  C S Loh; D Vernon; A J MacRobert; J Bedwell; S G Bown; S B Brown
Journal:  J Photochem Photobiol B       Date:  1993-09       Impact factor: 6.252

Review 6.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy.

Authors:  J C Kennedy; R H Pottier
Journal:  J Photochem Photobiol B       Date:  1992-07-30       Impact factor: 6.252

7.  Effect of 514.5-nm argon ion laser radiation on hematoporphyrin derivative-treated bladder tumor cells in vitro and in vivo.

Authors:  D A Bellnier; G R Prout; C W Lin
Journal:  J Natl Cancer Inst       Date:  1985-03       Impact factor: 13.506

8.  Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs.

Authors:  B A Goff; R Bachor; N Kollias; T Hasan
Journal:  J Photochem Photobiol B       Date:  1992-08-31       Impact factor: 6.252

9.  Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid.

Authors:  C S Loh; J Bedwell; A J MacRobert; N Krasner; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

10.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

Authors:  C S Loh; A J MacRobert; J Bedwell; J Regula; N Krasner; S G Bown
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  35 in total

1.  Enhancement of photodynamic therapy in gastric cancer cells by removal of iron.

Authors:  W C Tan; N Krasner; P O'Toole; M Lombard
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Dosedependent photodynamic effects of 9-acetoxy-2,7,12,17-tetrakis(\-methoxyethyl)-porphycene in vitro.

Authors:  S Karrer; R M Szeimies; A Ebert; S Fickweiler; C Abels; W Bäumler; M Landthaler
Journal:  Lasers Med Sci       Date:  1997-12       Impact factor: 3.161

3.  Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells.

Authors:  R Bachor; E Reich; A Rück; R Hautmann
Journal:  Urol Res       Date:  1996

Review 4.  Optical technologies for intraoperative neurosurgical guidance.

Authors:  Pablo A Valdés; David W Roberts; Fa-Ke Lu; Alexandra Golby
Journal:  Neurosurg Focus       Date:  2016-03       Impact factor: 4.047

Review 5.  Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives.

Authors:  F S De Rosa; M V Bentley
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

6.  Comparison between photodynamic therapy with topical application of 5-aminolevulinic acid and CO2 laser therapy in the treatment of cervical condylomata acuminate: a randomized controlled trial.

Authors:  Juan Du; Xiao-Nian Lu; Fei Li; Duo-Qin Wang; Ming Xu; Ying Sun; Jun Liang; Hui Tang; Yong-Sheng Yang; Zhen Zhang; Xiao-Hua Zhu; Jin-Ran Lin; Jin-Hua Xu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model.

Authors:  Pablo A Valdés; Kimberley Samkoe; Julia A O'Hara; David W Roberts; Keith D Paulsen; Brian W Pogue
Journal:  Photochem Photobiol       Date:  2009-12-07       Impact factor: 3.421

8.  Reduction of Uroporphyrinogen Decarboxylase by Antisense RNA Expression Affects Activities of Other Enzymes Involved in Tetrapyrrole Biosynthesis and Leads to Light-Dependent Necrosis.

Authors:  H. P. Mock; B. Grimm
Journal:  Plant Physiol       Date:  1997-04       Impact factor: 8.340

9.  Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.

Authors:  Sanjay Anand; Golara Honari; Tayyaba Hasan; Paul Elson; Edward V Maytin
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

10.  5-aminolevulinic acid ester-induced protoporphyrin IX in a murine melanoma cell line.

Authors:  Flavia C B Vena; Rozane F Turchiello; Isabelle Laville; Sophie Pigaglio; Jocelyne Blais; Antonio C Tedesco
Journal:  Lasers Med Sci       Date:  2004       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.